SunTrust Robinson Humphrey analyst, Peter Lawson, reiterated his Buy rating on shares of Clovis Oncology (NASDAQ: CLVS) but cut his ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE